Tudor Investment Corp’s Aimmune Therapeutics AIMT Stock Holding History

Tudor Investment Corp’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-989,506	Closed	-$34.1M	–	1761
2020 Q3	$34.1M	Buy	+989,506	New	+$21.1M	1.48%	5
2019 Q4	–	Sell	-28,722	Closed	-$601K	–	1464
2019 Q3	$601K	Buy	+28,722	New	+$586K	0.02%	657
2018 Q1	–	Sell	-8,555	Closed	-$324K	–	1348
2017 Q4	$324K	Sell	8,555 -6,330	-43%	-$204K	0.01%	779
2017 Q3	$369K	Buy	+14,885	New	+$321K	0.01%	749
2016 Q3	–	Sell	-11,400	Closed	-$123K	–	1827
2016 Q2	$123K	Buy	+11,400	New	+$155K	﹤0.01%	1498

Tudor Investment Corp's AIMT Position: Q4 2020 in Review

Tudor Investment Corp sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 989,506 shares — an estimated $34.1M sold.

Tudor Investment Corp first reported a position in AIMT in Q2 2016 and held it in 5 quarters. The position peaked at $34.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Tudor Investment Corp reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Tudor Investment Corp sold 989,506 Aimmune Therapeutics shares in Q4 2020, an estimated $34.1M.
Tudor Investment Corp first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 5 quarters.
Tudor Investment Corp's Aimmune Therapeutics position peaked at $34.1M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Tudor Investment Corp's 13F filing for Q4 2020, filed 16 Feb 2021.